Literature DB >> 15232339

Amoxapine in schizophrenia: a negative double-blind controlled trial.

Paul B Fitzgerald, Sacha Filia, Anthony De Castella, Nicole McBain, Shitij Kapur, Jayashri Kulkarni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15232339     DOI： 10.1097/01.jcp.0000132444.12607.33

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  3 in total

1.  Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia.

Authors:  Kevin C Reeves; Subhdeep Virk; Julie Niedermier; Anne-Marie Duchemin
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

Review 2.  Are second generation antipsychotics a distinct class?

Authors:  Caroline Bonham; Christopher Abbott
Journal:  J Psychiatr Pract       Date:  2008-07       Impact factor: 1.325

Review 3.  Antidepressants for people with both schizophrenia and depression.

Authors:  C Whitehead; S Moss; A Cardno; G Lewis
Journal:  Cochrane Database Syst Rev       Date:  2002
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.